Unknown

Dataset Information

0

A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of paclitaxel and 6?-hydroxy-paclitaxel in human plasma: Development, validation and application in a clinical pharmacokinetic study.


ABSTRACT: Paclitaxel belongs to the taxanes family and it is used, alone or in multidrug regimens, for the therapy of several solid tumours, such as breast-, lung-, head and neck-, and ovarian cancer. Standard dosing of chemotherapy does not take into account the many inter-patient differences that make drug exposure highly variable, thus leading to the insurgence of severe toxicity. This is particularly true for paclitaxel considering that a relationship between haematological toxicity and plasma exposure was found. Therefore, in order to treat patients with the correct dose of paclitaxel, improving the overall benefit-risk ratio, Therapeutic Drug Monitoring is necessary. In order to quantify paclitaxel and its main metabolite, 6?-hydroxy-paclitaxel, in patients' plasma, we developed a new, sensitive and specific HPLC-MS/MS method applicable to all paclitaxel dosages used in clinical routine. The developed method used a small volume of plasma sample and is based on quick protein precipitation. The chromatographic separation of the analytes was achieved with a SunFire™ C18 column (3.5 ?M, 92 Å, 2,1 x 150 mm); the mobile phases were 0.1% formic acid/bidistilled water and 0.1% formic acid/acetonitrile. The electrospray ionization source worked in positive ion mode and the mass spectrometer operated in selected reaction monitoring mode. Our bioanalytical method was successfully validated according to the FDA-EMA guidelines on bioanalytical method validation. The calibration curves resulted linear (R2 ?0.9948) over the concentration ranges (1-10000 ng/mL for paclitaxel and 1-1000 ng/mL for 6?-hydroxy-paclitaxel) and were characterized by a good accuracy and precision. The intra- and inter-day precision and accuracy were determined on three quality control concentrations for paclitaxel and 6?-hydroxy-paclitaxel and resulted respectively <9.9% and within 91.1-114.8%. In addition, to further verify the assay reproducibility, we tested this method by re-analysing the incurred samples. This bioanalytical method was employed with success to a genotype-guided phase Ib study of weekly paclitaxel in ovarian cancer patients treated with a wide range of drug's dosages.

SUBMITTER: Posocco B 

PROVIDER: S-EPMC5825125 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of paclitaxel and 6α-hydroxy-paclitaxel in human plasma: Development, validation and application in a clinical pharmacokinetic study.

Posocco Bianca B   Buzzo Mauro M   Follegot Andrea A   Giodini Luciana L   Sorio Roberto R   Marangon Elena E   Toffoli Giuseppe G  

PloS one 20180223 2


Paclitaxel belongs to the taxanes family and it is used, alone or in multidrug regimens, for the therapy of several solid tumours, such as breast-, lung-, head and neck-, and ovarian cancer. Standard dosing of chemotherapy does not take into account the many inter-patient differences that make drug exposure highly variable, thus leading to the insurgence of severe toxicity. This is particularly true for paclitaxel considering that a relationship between haematological toxicity and plasma exposur  ...[more]

Similar Datasets

| S-EPMC7533253 | biostudies-literature
| S-EPMC8954739 | biostudies-literature
| S-EPMC9379334 | biostudies-literature
| S-EPMC4538542 | biostudies-literature
| S-EPMC7292279 | biostudies-literature
| S-EPMC2980813 | biostudies-literature
| S-EPMC4551553 | biostudies-literature
| S-EPMC6550225 | biostudies-literature
| S-EPMC10071349 | biostudies-literature
| S-EPMC7764281 | biostudies-literature